Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer ...

JCR Pharmaceuticals’ unique brain-shuttling technology opens new treatment opportunities for meeting the needs of patients grappling with CNS diseases. Getting drugs from the bloodstream into ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

Vect-Horus’ versatile drug targeting technology uses receptor-mediated transport to deliver drugs or imaging agents to the brain and cancer tissues. The delivery of therapeutics to target areas ...